Log in to save to my catalogue

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium ab...

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium ab...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_149f66e121a54c98bc85751a4d79cc0e

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model

About this item

Full title

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model

Publisher

England: BioMed Central Ltd

Journal title

Annals of clinical microbiology and antimicrobials, 2025-01, Vol.24 (1), p.10-7, Article 10

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is uncertain. Inducible resistance to macrolides (macrolides-iR) has been associated with poor clinical re...

Alternative Titles

Full title

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_149f66e121a54c98bc85751a4d79cc0e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_149f66e121a54c98bc85751a4d79cc0e

Other Identifiers

ISSN

1476-0711

E-ISSN

1476-0711

DOI

10.1186/s12941-025-00776-w

How to access this item